We read with interest the letter by Ponzetto and co-workers [1] commenting on our recently published Point of View paper [2] . They propose the hypothesis that testing for Helicobacter pylori (HP), and, when positive, managing that underlying infection might improve the current management of patients with antiphospholipid syndrome (APS). They also highlight that HP's eradication might result in negativization for antiphospholipid antibodies (aPL) [3] . There are several mechanisms through which pathogens can initiate or perpetuate autoimmunity, and, while the factors causing production of aPL remain undefined, there is evidence that molecular mimicry is one of the mechanisms by which experimental APS can occur in association with certain pathogens [4] . However, when reviewing the available data on the topic, Abdel-Wahab et al. show that, although the development of aPL with all traditional manifestations of APS are observed after a variety of infections (mainly chronic viral infections including HIV and HCV), the causal relationship between infections and APS is still being debated [5] . Clinical evidence supports that infections can trigger the development of catastrophic APS. Nevertheless, the possible contribution of various infections in the pathogenesis of APS need further longitudinal and controlled studies to establish the incidence, and to better quantify the risk and the outcomes of aPL-related events after infection.
To date, the evidence supporting a role for HP eradication for the management of APS is too limited to include this approach in routine clinical practice. Besides, even if speculating that eradiating the HP might result in disappearance of aPL, an important clinical question still remains: is the aPL negativization enough to change the therapeutic approach in a patient with APS? Recent data suggest that a persistent negative aPL profile is not an indication to interrupt oral anticoagulant therapy as patients are still at high risk of recurrences [6] .
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